Focused On-demand Library for Protection of telomeres protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NUX5

UPID:

POTE1_HUMAN

Alternative names:

POT1-like telomere end-binding protein

Alternative UPACC:

Q9NUX5; O95018; Q5MJ36; Q9H662; Q9NW19; Q9UG95

Background:

Protection of telomeres protein 1 (POT1), also known as POT1-like telomere end-binding protein, plays a crucial role in telomere maintenance and protection. As a component of the telomerase ribonucleoprotein complex and the shelterin complex, POT1 is essential for the replication of chromosome termini, regulating telomere length, and safeguarding chromosome ends from DNA damage surveillance pathways.

Therapeutic significance:

POT1's involvement in diseases such as cutaneous malignant melanoma 10 and glioma 9 highlights its potential as a target for therapeutic intervention. Understanding the role of Protection of telomeres protein 1 could open doors to potential therapeutic strategies in combating these malignancies.